Elektrofi, Inc.
- UEI
- FSALANWTU197
- CAGE
- 7PML7
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- elektrofi.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Mrdc contract DHA sbir sequential PH II covid-19 pivot proposal no. H2S-0017 titled ultra-high concentration protein… | Medical Command (Army) | $1,499,982 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Oregon Health & Science University | R01DC018166 | $36,904 | |
| Oregon Health & Science University | R01AI154559 | $54,779 |
Similar vendors
About the company
Elektrofi, Inc. is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs.
Elektrofi, Inc. was awarded one prime federal contract, a $1.5 million firm fixed price definitive contract by the Defense Health Agency (DHA) to support Phase II of DHA's Small Business Innovation Research (SBIR) program. The contract calls for Elektrofi to deliver its ultra-high concentration protein delivery formulation technology to rapidly deploy treatments for COVID-19 and future pandemics. Research will be conducted over a two-year period in Boston, Massachusetts. The contract has a total small business set aside designation and is scheduled to conclude in November 2023.
Elektrofi, Inc. has been awarded five federal grant sub-awards from the National Institutes of Health (NIH) and the National Science Foundation (NSF). All five sub-awards supported research related to monoclonal antibody delivery systems, with the prime grantees being Oregon Health & Science University and an unnamed university. The research focused on areas such as development of long-acting CCR5 monoclonal antibodies for HIV transmission and enhanced environments for psychophysical evaluation and training.
Quick answers
Is Elektrofi, Inc. registered in SAM.gov?
Elektrofi, Inc.'s SAM.gov registration expired on February 9, 2024.
What is Elektrofi, Inc.'s most recent federal award?
Elektrofi, Inc.'s most recent federal contract award is Mrdc contract DHA sbir sequential PH II covid-19 pivot proposal no. H2S-0017 titled ultra-high concentration protein… (W81XWH21C0079), from Medical Command (Army), on July 2, 2021.
On GovTribe
See Elektrofi, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors